Keith A. Goldan - 09 Feb 2026 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Financial Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
09 Feb 2026
Net transactions value
-$71,705
Form type
4
Filing time
10 Feb 2026, 08:59:55 UTC
Previous filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Goldan Keith A. Chief Financial Officer 730 THIRD AVENUE, FLOOR 9, NEW YORK /s/ Michael A. Metzger, Attorney-in-Fact 10 Feb 2026 0001495411

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Sale $71,705 -3,410 -2.4% $21.03 140,429 09 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.